What does this research mean for the field?

Targeting platelet glycoprotein VI (GPVI) is a promising antiplatelet strategy for ischemic stroke that reduces thrombosis without significantly increasing bleeding risk in preclinical models, although clinical efficacy in Phase II/III trials has not yet been demonstrated. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to summarize the mechanisms and evidence supporting glycoprotein VI as a target for antiplatelet therapy in ischemic stroke.

March 30, 2026Thrombosis JournalOpen Access

Research advances on platelet glycoprotein VI in ischemic stroke

View Full Paper

Ask AI

Bookmark

Authors

HXHanlu Xiang KDKe Ding FMFanqiang Meng

Discussion

Member takes

Overview

A review highlights the potential of targeting glycoprotein VI for better antiplatelet therapy in ischemic stroke, suggesting improved outcomes without increased bleeding risk.

Key Points

This review aims to summarize the mechanisms and evidence supporting glycoprotein VI as a target for antiplatelet therapy in ischemic stroke.
Reviewed literature on GPⅥ's role in thrombus formation and ischemic stroke.
Analyzed data from preclinical models and clinical trials of anti-GPⅥ agents.
Evaluated safety and efficacy outcomes from existing studies.
Targeting GPⅥ can reduce thrombus formation and thromboinflammation in ischemic stroke models.
GPⅥ deficiency is linked to reduced platelet aggregation with minimal bleeding risk.
Recent Phase II/III trials of GPⅥ-targeting agents showed no positive efficacy outcomes in treating ischemic stroke.

Cite This Study

Xiang et al. (2026) studied this question.

synapsesocial.com/papers/69ca12d4883daed6ee09507c https://doi.org/10.1186/s12959-026-00859-4

View Full Paper

Ask AI

Bookmark

March 30, 2026Thrombosis JournalOpen Access

Research advances on platelet glycoprotein VI in ischemic stroke

View Full Paper

Ask AI

Bookmark

Authors

HXHanlu Xiang KDKe Ding FMFanqiang Meng

Discussion

Member takes

Overview

A review highlights the potential of targeting glycoprotein VI for better antiplatelet therapy in ischemic stroke, suggesting improved outcomes without increased bleeding risk.

Key Points

This review aims to summarize the mechanisms and evidence supporting glycoprotein VI as a target for antiplatelet therapy in ischemic stroke.
Reviewed literature on GPⅥ's role in thrombus formation and ischemic stroke.
Analyzed data from preclinical models and clinical trials of anti-GPⅥ agents.
Evaluated safety and efficacy outcomes from existing studies.
Targeting GPⅥ can reduce thrombus formation and thromboinflammation in ischemic stroke models.
GPⅥ deficiency is linked to reduced platelet aggregation with minimal bleeding risk.
Recent Phase II/III trials of GPⅥ-targeting agents showed no positive efficacy outcomes in treating ischemic stroke.

Cite This Study

Xiang et al. (2026) studied this question.

synapsesocial.com/papers/69ca12d4883daed6ee09507c https://doi.org/10.1186/s12959-026-00859-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark